Results 11 to 20 of about 882,729 (197)

Increased Platelet-derived Microparticles Counts is Correlated with Elevated Blood LDL Cholesterol in Acute Myocardial Infarction

Indonesian Biomedical Journal, 2022
BACKGROUND: Platelet-derived microparticles (PDMPs) and low-density lipoprotein (LDL) cholesterol are contributing factors to acute myocardial infarction (AMI).
Kelvin Supriami, Ira Puspitawati, Dyah Samti Mayasari, Anggoro Budi Hartopo   +3 more
doaj   +1 more source

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.

The Lancet Regional Health - Europe, 2023
Background European data pre-2019 suggest statin monotherapy is the most common approach to lipid management for preventing cardiovascular (CV) events, resulting in only one-fifth of high- and very high-risk patients achieving the 2019 ESC/EAS ...
K. Ray, I. Haq, A. Bilitou, M. C. Manu, A. Burden, C. Aguiar, M. Arca, D. Connolly, M. Eriksson, J. Ferrières, U. Laufs, J. Mostaza, D. Nanchen, E. Rietzschel, T. Strandberg, H. Toplak, F. Visseren, A. Catapano   +17 more
semanticscholar   +1 more source

Dyslipidemia and 10-year diabetes incidence in Japanese people: Population-based Panasonic cohort study 9

Frontiers in Endocrinology, 2022
Low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and LDL/HDL ratio have been associated with new-onset diabetes; however, their cut-off levels have not been determined.
Genki Kobayashi, Hiroshi Okada, Hiroshi Okada, Masahide Hamaguchi, Kazushiro Kurogi, Hiroaki Murata, Masato Ito, Michiaki Fukui   +7 more
doaj   +1 more source

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?

American Journal of Preventive Cardiology, 2020
It remains controversial whether reductions in cardiovascular mortality after intensive lowering of low density lipoprotein cholesterol (LDL-C) depend on baseline LDL-C levels.
Safi U. Khan, Erin D. Michos
doaj   +1 more source

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.

The Lancet Diabetes and Endocrinology, 2023
INTRODUCTION Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an acceptable
K. Ray, Roel P T Troquay, F. Visseren, Lawrence A Leiter, R. Scott Wright, S. Vikarunnessa, Z. Tallóczy, Xiao Zang, P. Maheux, Anastasia Lesogor, U. Landmesser   +10 more
semanticscholar   +1 more source

Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention

BMJ Open, 2022
Objective To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD).Design Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol ...
Handrean Soran, Safwaan Adam, Paul Durrington, Zohaib Iqbal   +3 more
doaj   +1 more source

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

Nature Biotechnology, 2021
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for ...
Tanja Rothgangl, Melissa K Dennis, Paulo J. C. Lin, Rurika Oka, D. Witzigmann, L. Villiger, W. Qi, M. Hrůzová, Lucas Kissling, Daniela Lenggenhager, Costanza Borrelli, S. Egli, Nina Frey, Noëlle Bakker, John A. Walker, A. Kadina, D. Victorov, Martin Pacesa, Susanne Kreutzer, Zacharias Kontarakis, A. Moor, M. Jinek, D. Weissman, M. Stoffel, R. van Boxtel, K. Holden, N. Pardi, B. Thöny, J. Häberle, Ying K. Tam, S. Semple, Gerald Schwank   +31 more
semanticscholar   +1 more source

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Elevated plasma levels of direct low‐density lipoprotein cholesterol (LDL‐C), small dense LDL‐C (sdLDL‐C), low‐density lipoprotein (LDL) triglycerides, triglycerides, triglyceride‐rich lipoprotein cholesterol, remnant lipoprotein particle ...
Hiroaki Ikezaki, Elise Lim, L. Adrienne Cupples, Ching‐Ti Liu, Bela F. Asztalos, Ernst J. Schaefer   +5 more
doaj   +1 more source

Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes.

Journal of Lipid Research, 1992
The aim of the present study was, first, to investigate whether cholesterol (C) absorption, enhanced by cholesterol feeding, was related to synthesis of cholesterol, serum level of low density lipoprotein (LDL)-C, and receptor activity for LDL ...
H Gylling, TA Miettinen
doaj   +1 more source

Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins

Clinical Research in Cardiology, 2017
BackgroundEuropean clinical guidelines recommend a low-density lipoprotein cholesterol (LDL-C) goal of  2 million individuals annually) to identify ASCVD (coronary atherosclerosis, stable/unstable angina, myocardial infarction, ischemic stroke, transient
K. Fox, M. Tai, K. Kostev, M. Hatz, Y. Qian, U. Laufs   +5 more
semanticscholar   +1 more source